Roy Moore, senior market analyst with HealthLeaders-InterStudy, is available to discuss managed care market implications of healthcare reform. Additionally, HealthLeaders-InterStudy has prepared an executive brief outlining how the Medicare, Medicaid and individual insurance markets will be affected, and what these changes mean for the pharmaceutical industry.
Mr. Moore can address the following topic areas:
To speak with Mr. Moore and receive a copy of the executive brief, contact Lisa Osgood at 781.296.2606 or firstname.lastname@example.org.
HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
/PR Newswire - March 25/
-- Health plans: winners and losers in the individual plan market. Managed care organizations that already have a foothold in the individual market are best positioned for enrolling the uninsured and include nonprofit Blue Cross Blue Shield plans, Humana and UnitedHealth Group. -- Medicare Advantage and Medigap. HealthLeaders-InterStudy predicts more seniors will migrate to Medigap, or Medicare supplement policies, because Medicare Advantage plans will be less attractive with the reimbursement cuts to participating managed care organizations outlined in the legislation. -- Medicaid and the pharmaceutical industry. The anticipated increase in Medicaid enrollment will put more pressure on the pharmaceutical industry to participate in rebate programs with states. Traditionally, states that have carved out pharma benefits from managed care companies have benefited from better rebates. Mr. Moore can provide examples of where these carve out programs are underway and how this market may change in light of reform.